cetylpyridinium has been researched along with Respiratory Tract Infections in 4 studies
Cetylpyridinium: Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges.
Respiratory Tract Infections: Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of a combined topical drug with flurbiprofen and cetylpyridinium chloride in patients with sore throat caused by upper respiratory tract infections." | 9.51 | [Results of a clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat]. ( Galustyan, AN; Gonik, MI; Sedavnykh, IS, 2022) |
| "Lozenges containing lidocaine and cetylpyridinium chloride (CPC) are commonly used for the treatment of sore throat." | 9.27 | Efficacy of 8 mg lidocaine and 2 mg cetylpyridinium chloride (CPC) fixed-combination lozenges on sore throat pain intensity compared with 1 mg lidocaine and 2 mg CPC fixed-combination lozenges in subjects with sore throat due to upper respiratory tract in ( Donath, F; Furcha, R; Garreffa, S; Mallefet, P, 2018) |
| "To evaluate the efficacy and safety of a combined topical drug with flurbiprofen and cetylpyridinium chloride in patients with sore throat caused by upper respiratory tract infections." | 5.51 | [Results of a clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat]. ( Galustyan, AN; Gonik, MI; Sedavnykh, IS, 2022) |
| "Lozenges containing lidocaine and cetylpyridinium chloride (CPC) are commonly used for the treatment of sore throat." | 5.27 | Efficacy of 8 mg lidocaine and 2 mg cetylpyridinium chloride (CPC) fixed-combination lozenges on sore throat pain intensity compared with 1 mg lidocaine and 2 mg CPC fixed-combination lozenges in subjects with sore throat due to upper respiratory tract in ( Donath, F; Furcha, R; Garreffa, S; Mallefet, P, 2018) |
| "Prior influenza vaccination had no effect on study outcome." | 2.84 | Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. ( Adkins, I; Arters, K; Buchheit, K; Esper, F; Ghannoum, MA; Mukherjee, PK; Salata, RA, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galustyan, AN | 1 |
| Sedavnykh, IS | 1 |
| Gonik, MI | 1 |
| Donath, F | 1 |
| Mallefet, P | 1 |
| Garreffa, S | 1 |
| Furcha, R | 1 |
| Mukherjee, PK | 1 |
| Esper, F | 1 |
| Buchheit, K | 1 |
| Arters, K | 1 |
| Adkins, I | 1 |
| Ghannoum, MA | 1 |
| Salata, RA | 1 |
| Haglind, K | 1 |
| Gruber, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel Group, Single-dose Study of the Efficacy of Lidocaine 8 mg + Cetylpyridinium Chloride (CPC) 2 mg Fixed Combination Lozenges on Sore Throat Pain Intensity Compared to Lozenges Containing Lidocaine 1 mg and CPC 2 mg in S[NCT01265446] | Phase 3 | 250 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo to Prevent Acute Upper Respiratory Disease and Respiratory Virus Infections[NCT02644135] | 100 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm) (NCT01265446)
Timeframe: Baseline and 2 hours post-dose
| Intervention | mm (Mean) |
|---|---|
| Lidocaine 8mg +CPC 2mg | -27.4 |
| Lidocaine 1mg + CPC 2mg | -26.9 |
100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm). It measures the highest pain level felt by the patient. (NCT01265446)
Timeframe: Baseline and 240 mn post-dose
| Intervention | mm (Mean) |
|---|---|
| Lidocaine 8mg +CPC 2mg | -25.5 |
| Lidocaine 1mg + CPC 2mg | -29.1 |
Measured by medical record review. (NCT02644135)
Timeframe: Through study duration, an average of 3 months
| Intervention | Number of acute respiratory illnesses (Number) |
|---|---|
| Halo Oral Spray | 4 |
| Halo Placebo | 2 |
(NCT02644135)
Timeframe: Through study duration, an average of 3 months
| Intervention | participants (Number) |
|---|---|
| Halo Oral Spray | 2 |
| Halo Placebo | 4 |
4 trials available for cetylpyridinium and Respiratory Tract Infections
| Article | Year |
|---|---|
[Results of a clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pharyngitis; Pro | 2022 |
Efficacy of 8 mg lidocaine and 2 mg cetylpyridinium chloride (CPC) fixed-combination lozenges on sore throat pain intensity compared with 1 mg lidocaine and 2 mg CPC fixed-combination lozenges in subjects with sore throat due to upper respiratory tract in
Topics: Administration, Oral; Adult; Anesthetics, Local; Anti-Infective Agents, Local; Cetylpyridinium; Doub | 2018 |
Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-Infective Agents, Local; Cety | 2017 |
[Testing of the effect of Imposit throat tablets in double-blind test].
Topics: Adolescent; Adult; Aged; Aminobenzoates; Benzyl Alcohols; Benzyl Compounds; Cetylpyridinium; Child; | 1975 |